Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
7.23M
-
Number of holders
-
33
-
Total 13F shares, excl. options
-
2.41M
-
Shares change
-
-202K
-
Total reported value, excl. options
-
$19.6M
-
Value change
-
-$1.76M
-
Number of buys
-
16
-
Number of sells
-
-20
-
Price
-
$8.13
Significant Holders of Atara Biotherapeutics, Inc. - Common Stock (ATRA) as of Q3 2024
48 filings reported holding ATRA - Atara Biotherapeutics, Inc. - Common Stock as of Q3 2024.
Atara Biotherapeutics, Inc. - Common Stock (ATRA) has 33 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2.41M shares
of 7.23M outstanding shares and own 33.39% of the company stock.
Largest 10 shareholders include EcoR1 Capital, LLC (469K shares), Redmile Group, LLC (452K shares), CITADEL ADVISORS LLC (260K shares), BANK OF AMERICA CORP /DE/ (204K shares), VANGUARD GROUP INC (181K shares), MILLENNIUM MANAGEMENT LLC (176K shares), ACADIAN ASSET MANAGEMENT LLC (129K shares), Vestal Point Capital, LP (125K shares), TANG CAPITAL MANAGEMENT LLC (75.2K shares), and RENAISSANCE TECHNOLOGIES LLC (67.7K shares).
This table shows the top 33 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.